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in a patient with a generalized urticarial reaction 
following denosumab administration
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Abstract 
Denosumab is a human monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women 
with a high risk of fractures. To our knowledge, no cases of desensitization to this drug have been described in the 
literature. We report the first case of generalized urticarial reaction and facial angioedema after therapy with deno‑
sumab. A subcutaneous desensitization protocol was successfully completed in this patient. Rapid desensitization 
is a promising method for the delivery of denosumab after a hypersensitivity reaction, and should be considered in 
osteoporosis treatment when no acceptable therapeutic alternatives are available.
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Background
Denosumab is a monoclonal antibody (mAb) used in 
the treatment of osteoporosis, approved by the FDA and 
the European Medicines Agency in 2010 [1]. The infu-
sion of this mAb may cause urinary tract infections and 
upper respiratory tract infections, sciatica, cataracts, 
constipation, limb pain and skin rashes, including a high 
incidence of eczema (3  %) [2]. The use of monoclonal 
antibodies is increasing but, despite their clinical utility, 
they have been associated with hypersensitivity reactions 
[3]. We present a desensitization protocol for denosumab 
in a patient with a generalized urticarial reaction and 
facial angioedema following the administration of this 
drug. To our knowledge, no cases of desensitization to 
denosumab have been described to date.
Case
We report the case of a 65-year-old woman with a history 
of hysterectomy at age 35, who presented generalized 
osteoporosis, severe bone pain and risk of bone fractures. 
The patient was referred from trauma management after 
failure of prior treatments for osteoporosis (bisphospho-
nates, alendronate and risedronic acid) after major side 
effects: gastrointestinal erosion with biphosphonates 
and alendronate, and severe gastrointestinal bleeding, 
severe muscle and joint pain, fever, flu symptoms, con-
junctivitis, episcleritis and uveitis with risedronic acid. 
All symptoms were intense and persistent. On the day 
after the first administration of denosumab the patient 
developed a generalized urticarial rash (thighs, abdo-
men, bilateral breast area, back) accompanied by bilat-
eral facial angioedema and pruriginous injuries in the 
area of drug administration (the abdomen) (Fig.  1). The 
symptoms started 2  h after the first administration and 
resolved completely after 15 days with the administration 
of antihistamines and oral corticoids and the application 
of local corticoids.
Informed consent was obtained from the patient to 
perform an allergy test. Skin prick test (SPT) with den-
osumab was performed 8 weeks after the initial adverse 
reaction in order to minimize the risk of false negative 
results. A commercial preparation of Prolia (Amgen 
Europe B.V., Breda, Netherlands; GlaxoSmithKline) was 
used, containing 60 mg of denosumab in each preloaded 
1  ml syringe (60  mg/ml). Histamine prick (10  mg/ml) 
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and saline solution were used as positive and negative 
controls. A positive reaction was defined as a wheal with 
a diameter at least 3 mm larger than that obtained by a 
negative control. For SPT, a drop of denosumab (60 mg/
ml) was applied and pricked to the volar surface of the 
forearm, eliciting a negative response. For intradermal 
testing, denosumab was diluted in normal saline. We 
proceeded with intradermal injections of 0.03 ml of 1/100 
and 1:10 dilution of the denosumab strength solution, 
which obtained negative results. These concentrations 
proved to be non-irritating in ten control subjects who 
had never been treated with denosumab. The patch test 
with undiluted drug was applied at both the upper back 
and the previous local injection site, and also produced 
negative results. Skin prick test to house dust mites, cat 
and dog dander, olive, grass pollen and latex were nega-
tive, as was serum specific IgE to latex dander.
Given the risk of bone fracture and the numerous side 
effects of the conventional therapies for the treatment 
of osteoporosis, the patient agreed to denosumab treat-
ment using a desensitization protocol. After informed 
consent was given, the desensitization procedure was 
performed. Blood pressure and heart rate were moni-
tored during the test. The patient was pre-medicated 
with methylprednisolone (40 mg IV), ranitidine (50 mg 
IV) and dextrochloropheniramine (5 mg IV) 1 h before 
drug administration. A desensitization protocol was 
begun with an initial subcutaneous dose of 0.005  mg 
which was gradually increased in an eight-step cycle 
until a cumulative dose of 60 mg was reached (Table 1). 
The interval between doses was 15 min and the process 
was completed in 2  h. No local or systemic reactions 
were observed, either immediate or delayed. Since then, 
the patient has tolerated other two cycles of denosumab 
desensitization using only antihistamines for premedi-
cation, and her osteoporosis has evolved favourably.
In order to demonstrate the efficacy of our desensitiza-
tion procedure, a denosumab provocation was performed 
6  months after the third desensitization protocol. After 
3  h the patient presented bilateral angioedema, which 
had not occurred in the previous cycles of denosumab 
desensitization. On the next day, the patient had a very 
pronounced angioedema of the eyelids and cheekbones. 
Tryptase levels were 2.3 ng/ml (negative up to 15 ng/ml) 
before the challenge test, 2.1  ng/ml after the challenge 
Fig. 1 Bilateral facial angioedema one day after the first administra‑
tion of denosumab
Table 1 Desensitization protocol for denosumab
No adverse reactions were observed during the desensitization process
Blood pressure at baseline: 149/77; arterial pulse at baseline: 89
The four higher doses were prepared introducing the necessary volume from the original syringe (60 mg/ml) into four insulin syringes (0.55, 0.25, 0.125 and 0.05 ml 
respectively). For the four smaller doses, appropriate dilutions were made with saline solution, starting from the original syringe. The solutions were valid for 24 h, and 
were protected from light and refrigerated
Dose (mg) Cumulative dose  
(mg)




0.005 – 0 166/77 87
0.05 – 15 152/65 84
0.5 – 30 147/73 80
1.5 1.5 45 145/73 67
3 4.5 60 150/72 73
7.5 12 75 166/82 70
15 27 90 149/81 68
33 60 105 144/73 76
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test, and finally 2.2  ng/ml after desensitization. Apply-
ing our desensitization procedure once again using only 
antihistamines as premedication, the drug was perfectly 
tolerated.
Discussion
We report the first case of a delayed generalized skin 
reaction (urticaria and angioedema) occurring several 
hours after the first administration of denosumab. To our 
knowledge, no such adverse reaction after administration 
of this drug has previously been reported. We describe 
the first rapid desensitization protocol for denosumab. 
The cumulative therapeutic dose was reached in 2 h, and 
the protocol was successfully completed.
mAbs can cause infusion-related reactions but the 
exact etiology of these events remains unclear. They may 
arise via immunoglobulin (Ig) E- or non-IgE-dependent 
mechanisms [3]. Although an IgE-mediated mechanism 
was not confirmed by skin tests, our patient was empiri-
cally desensitized because the nature of the reactions 
indicated hypersensitivity. IgE- and non-IgE-sensitized 
patients may present with similar symptoms, indicating 
that mast cells and/or basophils are the cellular targets of 
these reactions. Nevertheless, in these patients, desen-
sitization is a therapeutic procedure that aims to induce 
a temporary tolerance to the drug responsible for the 
hypersensitivity reaction. Rapid desensitization can be 
used for both IgE-mediated and non-IgE-hypersensitivity 
reactions [4].
The rates of hypersensitivity reactions that are clinically 
consistent with hypersensitivity to specific monoclonal 
antibodies have been reported to be 5–10  % for rituxi-
mab, 2–3 % for infliximab, and 0.6–5 % for trastuzumab 
[5]. Hypersensitivity reactions have also been reported 
for omalizumab, natalizumab, basiliximab, abciximab, 
adalimumab and cetuximab. In fact, desensitization pro-
tocols have been carried out with some of these biologi-
cal agents, achieving therapeutic doses in patients who 
had presented anaphylactic or anaphylactoid reactions 
during treatment [6–8]. However, no guidelines for deno-
sumab desensitization have been published to date.
A limitation of this study was the fact that the basophil 
activation test was not performed during the reaction. 
Nevertheless, the tryptase levels obtained indicated that 
there was no mast cell or IgE involvement.
In conclusion, we report the first case of generalized 
urticarial reaction and facial angioedema after therapy 
with denosumab. A subcutaneous desensitization pro-
tocol was successfully completed in this patient. The 
drug challenge results and the repeated high tolerance 
of our desensitization method without glucocorticoid 
premedication confirmed the etiology of reaction and the 
efficacy of the protocol, independently of the drug used 
to reduce adverse effects during the procedure. Rapid 
desensitization is a promising method for the delivery of 
monoclonal antibodies after hypersensitivity reactions, 
and should be considered in osteoporosis treatment 
when there are no acceptable therapeutic alternatives.
Authors’ contributions
DGF, AFF AMA, MJFA and FMV: Conception and design of the study; DGF, AMA, 
MJFA, FMV, AGJA, MJC: data generation; DGF, AFF, MJC, AMA, FMV, AGJA, MJFA: 
analysis and interpretation of the data and DGF, AFF and MJC: preparation 
and critical revision of the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Pneumology‑Allergy Department, Puerta del Mar University Hospital, Cádiz, 
Spain. 2 Servei de Pneumologia, Hospital Universitari Vall d’Hebron, Passeig Vall 
d’Hebron, 119, 08035 Barcelona, Spain. 3 Joaquín Pece Primary Care Centre, 
San Fernando, Cádiz, Spain. 4 Allergy Department, Hospital Nuestra Señora 
del Prado, Talavera de la Reina, Toledo, Spain. 5 Hospital Pharmacy, Puerta del 
Mar University Hospital, Cádiz, Spain. 6 Unidad de Gestión Clínica Aparato 
Locomotor, Rheumatology Department, Puerta del Mar University Hospital, 
Cádiz, Spain. 7 Unidad de Gestión Clínica Aparato Locomotor, Orthopaedic 
Surgery and Traumatology Department, Puerta del Mar University Hospital, 
Cádiz, Spain. 
Acknowledgements
MJC is a researcher supported by the Miguel Servet programme of the Insti‑
tuto de Salud Carlos III (CP12/03101).
Competing interests
The authors declare that they have no competing interests.
Received: 27 July 2015   Accepted: 6 October 2015
References
 1. Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Deno‑
sumab for prevention of fractures in postmenopausal women with 
osteoporosis. N Engl J Med. 2009;361:33–41.
 2. Rizzoli René. Adverse drug reactions to osteoporosis treatments. Expert 
Rev Clin Pharmacol. 2011;4(5):593–604.
 3. Chung CH. Managing premedications and the risk for reactions to infu‑
sional monoclonal antibody therapy. Oncologist. 2008;13:725–32.
 4. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions 
to chemotherapy: outcomes and safety of rapid desensitization in 413 
cases. J Allergy Clin Immunol. 2008;122(3):574–80.
 5. Castells Guitart MC. Rapid drug desensitization for hypersensitivity reac‑
tions to chemotherapy and monoclonal antibodies in the 21st century. J 
Investig Allergol Clin Immunol. 2014;24(2):72–9.
 6. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hyper‑
sensitivity reactions to mAbs: 105 desensitizations in 23 patients, from 
evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–66.
 7. Foncubierta Fernandez A, Gutierrez Fernandez D, Espinosa Rosso R, 
Anguita Carazo J, Fernandez Melendez S, Miranda Paez A. Desensitization 
protocol in a patient with immediate hypersensitivity to apomorphine. J 
Allergy Clin Immunol. 2012;129(2):AB185.
 8. Gutiérrez‑Fernández D, Foncubierta‑Fernández A, Anguita‑Carazo JL, 
Fernández‑Meléndez S, Fernández‑Anguita MJ, Medina‑Varo F. Adali‑
mumab desensitization protocol in a patient with a generalized urticarial 
reaction and angioedema following adalimumab administration. J Clin 
Immunol Investig Allergol. 2014;24(4):267–85.
